An open-label, balanced, randomized, two-treatment, two-sequence, two-period, single dose, crossover relative bioavailability study of Glimepiride Oral Disintegration Strip 1 mg manufactured by: ZIM Laboratories, Nagpur, India, manufactured for: Sanofi Healthcare India Private Limited and Amaryl (Glimepiride) Tablet 1 mg Manufactured by Sanofi-Aventis Deutschland GmbH, Germany in healthy adult human subjects under fasting conditions. (Project Number: AZBE022406, Sponsor Study Code: BDR16756, Version: 1.0, Date: 09-APR-2024). - NIL

开始日期2024-11-29

申办/合作机构

Sanofi Healthcare India Pvt Ltd.

CTRI/2024/11/076291

/ Not yet recruitingN/A

An open-label, balanced, randomized, two-treatment, two-sequence, two-period, single dose, crossover relative bioavailability study of Glimepiride Oral Disintegration Strip 1mg manufactured by: ZIM Laboratories, Nagpur, India, manufactured for: Sanofi Healthcare India PrivateLimited and Amaryl (Glimepiride) Tablet 1 mg Manufactured by Sanofi-Aventis Deutschland GmbH,Germany in healthy adult human subjects under fed conditions. (Project Number: AZBE022407, SponsorStudy Code: BDR17557, Version: 1.0, Date: 09-APR-2024) - NIL

开始日期2024-11-29

申办/合作机构

Sanofi Healthcare India Pvt Ltd.

100 项与格列美脲相关的临床结果

登录后查看更多信息

100 项与格列美脲相关的转化医学

登录后查看更多信息

100 项与格列美脲相关的专利（医药）

登录后查看更多信息

3,749

项与格列美脲相关的文献（医药）

2025-12-01·Current Diabetes Reports

From Glucose Control to Multifaceted Benefits: The Rise of Modern Sulphonylureas in Diabetes Care

Review

作者: Dhingra, Atul ; Tuladhar, Jasmin ; Shakya, Santosh ; Shrestha, Dina

PURPOSE OF REVIEW:

This review aims to highlight the evolution and multifaceted benefits of modern sulfonylureas (SUs) in managing Type 2 Diabetes Mellitus (T2DM). It discusses their enhanced glycemic control, pleiotropic advantages, usage with other antidiabetic agents, safety, and tolerability, supporting their persistent relevance and effectiveness in diabetes care.

RECENT FINDINGS:

Recent findings indicate that modern SUs, like glimepiride, offer significant cardioprotective and renoprotective benefits along with their primary role in glycemic control. Additionally, they have also shown their anti-inflammatory effects, lipid-lowering properties, testosterone-enhancing effects, and neuroprotective effects in recent years. These findings support the broader therapeutic advantages of modern SUs beyond glucose lowering. Hence, many guidelines now recommend modern SUs as an add-on therapy to metformin. Modern sulfonylureas remain a vital component in T2DM management strategy due to their efficacy, safety profile, and cost-effectiveness. Their pleiotropic benefits, like cardiovascular, renal, anti-inflammatory, neuroprotective effects, etc., make them a comprehensive therapeutic option. Considering their efficacy and safety profile, SUs are expected to remain vital components of antidiabetic therapy, providing valuable benefits in managing T2DM in the long run.

2025-07-01·JOURNAL OF MOLECULAR STRUCTURE

Quercetin capped Au-Ag bimetallic nanoparticles for the detection of calcium dobesilate monohydrate in biological and environmental samples

作者: Qayoom, Amtul ; Asrar, Shaz ; Hussain, Dilshad ; Ali, Saeeda Nadir

The study details the synthesis of quercetin-capped Au-Ag bimetallic nanoparticles (Qct-AuAg BMNps) in an aqueous environment.UV visible spectra showed absorbance peak of gold and bimetallic nanoparticles at 524 nm and 403 nm, resp.The SEM anal. of Qct-AuAg BMNps showed an average particle size of 67.5 nm with good uniformity (PdI: 0.386).FTIR confirmed the presence of resp. functional groups in Qct-AuAg BMNps.The Qct-AuAg BMNps were used as a colorimetric sensor for detecting calcium dobesilate monohydrate (CDM) in aqueous solutions, showing a linear spectrophotometric relationship with CDM concentration ranging from 0.000001 mM to 10 mM (R² = 0.9984).The detection and quantification limits were 1.66 x 10^-6 and 2.71 x 10^-5 mM, resp.The binding constant (K_a) was 9.8 x 10⁴ M^-1, with a 1:1 stoichiometry confirmed by Job's plot.The Qct-AuAg BMNps were successfully used to detect CDM in tap water and serum samples.The synthesis process was optimized using Box Behnken Design, with the optimal conditions found at 50°C, 2 mM quercetin, and a 5:1 silver-to-gold ratio.Therefore, the synthesized quercetin capped gold silver bimetallic nanoparticles were proved effective for the detection of CDM in liquid samples.

2025-06-01·DIABETES CARE

Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial

Article

OBJECTIVE:

Weight gain with glucose-lowering medications may interfere with effective type 2 diabetes (T2D) management. We evaluated weight change and the effect of weight gain on outcomes over 5 years on four diabetes medications.

RESEARCH DESIGN AND METHODS:

The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) randomized trial compared the addition of insulin glargine, glimepiride, liraglutide, or sitagliptin to metformin in participants with T2D. We report weight change and hazard ratio (HR) per kilogram of weight change for HbA1c >7.5%; cardiovascular disease (CVD), kidney disease, and neuropathy outcomes; and diabetes treatment satisfaction.

RESULTS:

Participants (n = 4,980) were 57 ± 10 years, 44% non-White, with HbA1c 7.5% ± 0.5%, and BMI 34.3 ± 6.8 kg/m2. Mean (95% CI) weight change (kg) during the first year was −3.5 (−3.8,−3.2) with liraglutide,−1.07 (−1.4,−0.78) with sitagliptin, 0.45 (0.16, 0.74) with glargine, and 0.89 (0.60, 1.2) with glimepiride (P < 0.0001). Thereafter, weight decreased in all groups. Weight gain within the first 6 months was associated with increased risk of HbA1c >7.5%, with modest differences by treatment, and with subsequent CVD (HR 1.03 [95% CI 1.005, 1.06]). Weight gain at 1 year was associated with increased risk of HbA1c >7.5% (HR 1.05 [1.04, 1.07]) and kidney disease (HR 1.03 [1.01, 1.06]). Baseline weight, but not weight gain, was associated with new-onset neuropathy. Weight gain was associated with lower diabetes treatment satisfaction.

CONCLUSIONS:

Liraglutide and sitagliptin were associated with initial weight loss and glargine and glimepiride with slight weight gain, followed by weight loss in metformin-treated T2D. Weight gain was associated with worsening glycemia and increased risk of cardiovascular and kidney outcomes largely independent of treatment.

项与格列美脲相关的新闻（医药）

2025-05-21

·ETPharma

196 Drug Samples Fail CDSCO Quality Test; One Deca-Durabolin Sample Flagged as Spurious

New Delhi: Drug regulators, during their monthly quality review, have identified around 196 drug samples as “ Not of Standard Quality ” (NSQ) and one sample as “spurious.” The drug alert issued by the Central Drugs Standard Control Organization ( CDSCO ) states that out of the 196 NSQ samples, 60 were identified by central drug laboratories, while the remaining 136 were flagged by state laboratories. In addition, one drug sample identified as spurious is a “ Nandrolone Decanoate Injection,” marketed as Deca-Durabolin —an anabolic steroid used for various medical conditions, including osteoporosis and anemia. According to a note from the Union Health Ministry , the spurious sample was picked from Bihar and “is manufactured by an unauthorized manufacturer using the brand name owned by another company.” In its alert, the CDSCO specified that the tested sample failed due to issues with the “Identification and Assay of Nandrolone Decanoate .” In India, “Deca-Durabolin 50 mg” is marketed by Ahmedabad-based Zydus Healthcare, following its acquisition of the brand from MSD (Merck Sharp & Dohme) in December 2016. The matter is currently under investigation, and the purported spurious drug is subject to the outcome of the inquiry. A drug is deemed spurious if it resembles another drug in a manner likely to deceive, or if it bears upon its label or container the name of another drug—among several other conditions detailed under Section 17-B of the Drugs and Cosmetics Act, 1940. Among the 60 NSQ samples flagged by central laboratories are Nimesulide and Paracetamol tablets manufactured by Pro-Pharma Care; Cefpodoxime Proxetil tablets by Sunvij Drugs; Ciprofloxacin tablets by Cadila Pharmaceuticals; and 57 other samples. The 136 NSQ samples identified by state laboratories include Glimepiride 1 mg and Metformin HCl 500 mg tablets manufactured by Surge Pharmaceuticals; Albendazole tablets by Samkem; and Oxfendazole and Ivermectin Bolus by Argon Remedies, among 133 other samples. The identification of drug samples as NSQ is based on the failure of the sample to meet one or more specified quality parameters. The term NSQ is defined under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940. However, according to the Health Ministry, “the failure is specific to the drug products of the batch tested by the Government Laboratory and does not warrant concerns about other drug products available in the market.” The ministry added that the identification of NSQ and spurious medicines is undertaken regularly (monthly), in collaboration with state regulators, to ensure such drugs are detected and removed from the market. By Online Bureau ,

并购上市批准

2025-04-18

·ETPharma

131 drugs fail CDSCO quality test, another Telma sample flagged as spurious

New Delhi: During the routine quality review check in March, a total of 131 drug samples failed to meet the quality standards, while one sample of the popular hypertension brand Telma 40 has been flagged as spurious. The monthly drug quality review alert issued by the Central Drugs Standard Control Organization (CDSCO) flagged 131 drug samples as “ Not of Standard Quality ” (NSQ) and one sample as “spurious.” Making the announcement, the Union Health Ministry informed that of the total 131 NSQ samples, 70 were identified by the Central Drugs Laboratories and the remaining 61 samples were identified by the State Drugs Testing Laboratories. In addition to this, one drug sample flagged as spurious is of popular hypertension brand “Telma 40 (Telmisartan Tab I.P. 40mg),” manufactured in February 2024 and was plucked by the regulators from West Bengal. As per the Union Health Ministry, “the spurious sample was manufactured by an unauthorized manufacturer using a brand name owned by another company, and currently the matter is under investigation.” In its remark, the apex drug regulator CDSCO has said, “the product is purported to be spurious, however, the same is subject to the outcome of investigation.” Notably, last month a separate batch of the same brand picked from West Bengal was flagged as spurious. The sample was manufactured in 2022, and the reason for the drug test failure was notified as the sample “does not conform to I.P.” Telma (Telmisartan) is an angiotensin II receptor blocker that decreases high blood pressure and has been commercially marketed in India for the past two decades. The branded generic drug is marketed by Glenmark and, as per an analysis from market research firm Pharmarack, it features among the top 20 brands in the country, with a moving annual total (MAT) value of around ₹483 crore. The NSQ drug samples flagged by the central drug laboratories in March include Pantoprazole manufactured by Kolkata-based Shangrila Industries; Albendazole tablets by Mumbai-based Digital Vision; Telmisartan tablets manufactured by Guwahati-based Swiss Garnier Life Sciences; among 67 others. While the NSQ samples identified by state drug testing laboratories include Norfloxacin tablets manufactured by Revat Laboratories; Glimepiride tablets by Kerala State Drugs and Pharmaceuticals; Sucralfate by Legend Industries; among 58 others. Under Section 17-B of the Drugs and Cosmetics Act, 1940, a drug shall be deemed spurious if it is manufactured under a name belonging to another drug; an imitation of, or a substitute for, another drug; resembles another drug in a manner likely to deceive; or if it bears upon its label or container the name of another drug, among several other provisions. For NSQ samples, the drugs that fail to meet quality standards or specifications are notified as NSQ, a term defined under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940. By Online Bureau ,

2025-04-07

·米内网

这家山东药企发威！独家产品“11连涨”，29个新品抢攻160亿市场，1类新药火力全开

精彩内容近日，山东新华制药公布了2024年业绩，营业收入创出新高达84.66亿元。近几年公司积极开拓市场，2024年全年收获了12个新产品，正式入局抗痛风制剂市场，今年以来再有5个新品获批，首款吸入剂面世。在中国公立医疗机构终端，公司在2024上半年成功挤进4个热销品类市场TOP30集团之列。目前，公司的1类新药OAB-14干混悬剂处于II期临床前准备阶段，29个报产在审的新品将抢攻160亿市场，公司积极转型，未来可期。拿下17个重磅新品，240亿市场大突破据悉，山东新华制药的主营业务包括了开发、制造和销售化学原料药、制剂及化工产品，主要产品为“新华牌”解热镇痛、心脑血管、抗感染及中枢神经等多类药物。据年报数据显示，2024年公司的化学原料药营收超过27亿元，同比有所下降，而制剂营收则超过了40亿元，同比增长了11.91%，医药中间体及其他营收也超过了16亿元，同比增长了23.56%。公司通过“自主研发+技术转让”不断丰富产品线，据公司公告统计，2024年全年拿下了12个新品（含持有人变更），2025年至今也有5个新品收入囊中。表1：山东新华制药2024年至今获批的产品情况来源：公司公告、米内网整理山东新华制药旗下淄博新达制药的非布司他片4类仿制上市申请在2024年11月获批并视同过评，该产品是公司首款获批的抗痛风制剂。2023年在中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端抗痛风制剂市场，非布司他片是TOP1产品。2025年1月，山东新华制药通过技术转让获得了盐酸左沙丁胺醇雾化吸入溶液，该产品是公司首款获批的吸入剂。2023年在中国公立医疗机构终端吸入剂（化+中+生）合计的市场规模在240亿元以上，盐酸左沙丁胺醇雾化吸入溶液是TOP7产品。11个独家产品亮眼，领跑4个热销品类市场截至目前，山东新华制药已有超过250个药品获批上市，均为化学药，其中独家产品占了11个，阿司匹林肠溶缓释片近几年销售一路飞涨，已成为亿元级别的热销抗血栓形成药。表2：山东新华制药的独家产品情况来源：米内网中国上市药品（MID）数据库图1：阿司匹林肠溶缓释片的销售情况（单位：万元）来源：米内网中国公立医疗机构终端竞争格局山东新华制药的独家产品阿司匹林肠溶缓释片用于抑制血小板粘附和聚集，减少动脉粥样硬化患者的心肌梗塞、暂时性脑缺血或中风发生。在中国公立医疗机构终端，该产品的销售额连续11年保持正增长态势，2022-2023年销售额在1亿元以上，2024上半年增长率超过3%，是抗血栓形成药（化+生）市场内服TOP15产品。在中国公立医疗机构终端，山东新华制药的热销产品分布在30多个亚类市场，2024上半年公司已成功挤进4个热销品类市场TOP30集团（一级，下同）之列，成绩亮眼。2023年在中国公立医疗机构终端阻塞性气管疾病用药（化+生）的市场规模在210亿元以上，2024上半年新华制药排在TOP29集团，公司在该类药物市场的热销产品包括了氨茶碱注射液、茶碱缓释片、氨茶碱片等。2023年在中国公立医疗机构终端维生素类化药的市场规模在150亿元以上，2024上半年新华制药排在TOP28集团，公司在该类药物市场的热销产品包括了维生素C注射液、维生素B6注射液、维生素C片等。2023年在中国公立医疗机构终端其它所有治疗用药品（化+生）的市场规模接近60亿元，2024上半年新华制药排在TOP17集团，公司在该类药物市场的热销产品包括了盐酸纳洛酮注射液、碳酸司维拉姆片、乙酰胺注射液。2023年在中国公立医疗机构终端其它治疗皮肤病药物（化+生）的市场规模超过30亿元，2024上半年新华制药排在TOP14集团，公司在该类药物市场的热销产品是乙氧苯柳胺软膏（独家）。1类新药加速推进，29个高端仿制药在路上据公司年报数据显示，2024年山东新华制药的研发投入约为3.97亿元，占公司总营收比例为4.69%。年报中还提到，公司的化药1类新药OAB-14干混悬剂正处于II期临床前准备阶段。图2：OAB-14干混悬剂的临床情况来源：米内网中国临床试验数据库据悉，OAB-14干混悬剂是一款全新的抗AD药物，能显著减少脑内β淀粉样蛋白沉积，降低Tau蛋白过度磷酸化，同时保护大脑皮层及海马神经细胞及突触结构与功能，该新药临床拟用于治疗轻至中度阿尔茨海默病。表3：山东新华制药目前报产在审的新产品来源：米内网中国申报进度（MED）数据库目前山东新华制药报产在审的新产品有29个，均为高端仿制药，2023年在中国公立医疗机构终端的销售额合计超过160亿元。随着新品陆续获批，公司的产品矩阵将越来越丰富，竞争力将持续提升。29个新品分布在21个亚类市场，目前公司暂无抗帕金森氏病药、其它消化道和代谢用药获批，恩他卡朋片、左卡尼汀口服溶液若顺利获批将为公司拓展两个新市场。64个产品已过评，7个爆款备战第十一批国采2019年5月，山东新华制药的格列美脲片一致性评价补充申请获批，成为了公司首个过评产品，截至2025年4月6日公司过评/视同过评的产品达64个。山东新华制药积极参与国家集中带量采购，在第二批、第三批、第四批、第七批、第八批、第九批、第十批国采中共有19个产品中标。表4：山东新华制药国采中标产品最新市场情况来源：米内网中国公立医疗机构终端竞争格局国采落地加速了产品的企业格局洗牌，2024上半年在中国公立医疗机构终端，山东新华制药成为了布洛芬片、盐酸吡格列酮胶囊、复方磺胺甲噁唑片、氨茶碱注射液的龙头企业，也是吡拉西坦注射液的TOP2企业。表5：山东新华制药备战第十一批国采的产品注：销售额低于1亿元用*表示来源：米内网中国公立医疗机构终端竞争格局截至目前，山东新华制药已过评/视同过评且未纳入国采的产品中有7个产品的竞争企业（原研+过评）在7家或以上，公司上述产品为近五年获批的新品或暂未在市场上放量的“光脚产品”，若顺利纳入第十一批国采且中标，有望助力公司进一步抢占市场。值得注意的是，上述产品目前的竞争企业数量十分惊人，可以预见新一轮激战已无可避免，最终结果我们静待官宣。来源：公司年报、米内网数据库等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至4月6日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

财报上市批准

100 项与格列美脲相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00593	格列美脲	A10BB12	DB00222

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病	美国	Sanofi-Aventis U.S. LLC	1995-11-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ADA2024	N/A	2型糖尿病	-	Glimepiride 1mg/Vildagliptin 50mg/Metformin 500mg	顧網構鹽築構簾範鹽獵(範壓膚廠夢選鑰醖鑰壓) = Three mild hypoglycemic events were reported with the starting dose 網簾廠餘壓襯簾鑰鬱齋 (願顧顧顧鏇鬱憲齋壓製 )	-	2024-06-14
				Glimepiride 2mg/Vildagliptin 50mg/Metformin 1000mg
FRI651 (ENDO2023)	N/A	2型糖尿病一线	470	Glimepiride and Metformin FDC	網窪獵鑰淵簾鹹築獵簾(廠齋構積夢淵選衊遞餘) = 窪鏇範觸壓鬱積淵衊鹹憲淵遞築繭襯鑰糧積製 (夢襯選遞廠壓襯觸憲膚 ) 更多	-	2023-10-05
NCT05538819 (Pubmed \| Eur J Prev Cardiol)	N/A	2型糖尿病 \| 慢性心力衰竭	-	Glimepiride treatment	顧網鹽鹹選觸簾齋衊鏇(鹽蓋構廠餘範夢選醖艱): HR = 0.47 (95% CI, 0.35 ~ 0.63) 更多	-	2022-12-27
				No glimepiride treatment
NCT01794143 (GRADE, ASN2022)	临床3期	2型糖尿病	-	Sitagliptin	廠醖齋鬱壓餘觸糧鹽淵(壓鹽膚繭夢壓獵鹽齋網) = 艱鑰壓構積製鏇廠鏇鬱廠鹽餘鏇齋繭淵醖廠窪 (窪鏇壓選醖觸壓簾顧遞, -2.20 ~ -1.86)	不佳	2022-11-03
				Glimepiride	廠醖齋鬱壓餘觸糧鹽淵(壓鹽膚繭夢壓獵鹽齋網) = 築繭顧醖膚鹽鏇鬱蓋襯廠鹽餘鏇齋繭淵醖廠窪 (窪鏇壓選醖觸壓簾顧遞, -2.08 ~ -1.75)
GRADE Study (ADA2022)	N/A	低血糖	-	Glimepiride	襯遞積遞齋繭壓壓製鬱(獵網構簾繭鬱糧鑰糧構) = 襯蓋襯網壓觸製艱襯餘廠壓壓艱鏇鹽簾夢網蓋 (蓋壓簾窪糧蓋廠壓壓遞 ) 更多	-	2022-06-01
				Insulin Glargine	襯遞積遞齋繭壓壓製鬱(獵網構簾繭鬱糧鑰糧構) = 膚鹹選蓋壓鹹網鏇壓觸廠壓壓艱鏇鹽簾夢網蓋 (蓋壓簾窪糧蓋廠壓壓遞 ) 更多
NCT01167881 (EMPA-REG H2H-SU, Pubmed \| J Comp Eff Res)	临床3期	2型糖尿病	1,549	Empagliflozin+metformin	艱襯顧構範齋鏇衊網窪(鏇鏇夢繭願範襯遞構築) = 簾淵觸範願糧襯衊鏇範獵衊壓繭窪積構簾觸選 (鏇衊壓淵構膚糧觸淵鹹 )	-	2021-02-12
EUCTR2017-000204-15-DK (EASD2020)	临床2期	成年发病型糖尿病3型追加	20	Glimepiride+Linagliptin	齋窪積獵鏇艱膚獵糧餘(鬱遞艱鬱鹽繭壓襯繭餘) = 獵鬱壓遞網夢衊構選築積襯窪艱齋範艱衊膚襯 (襯鏇艱遞鏇顧觸壓膚鏇, -7.1 ~ -0.3) 更多	积极	2020-09-24
ADA2020	N/A	糖尿病追加	19	glimepiride + linagliptin	糧鬱鑰壓繭鹽繭鹹範廠(糧鏇範膚夢繭醖夢餘獵) = 鹽糧簾夢鹽觸鹹網遞繭鑰築膚積鬱遞衊憲觸壓 (壓遞襯夢顧醖糧淵蓋廠 )	-	2020-06-01
ADA2020	N/A	2型糖尿病追加	-	Dapagliflozin 10 mg/d + Saxagliptin 5 mg/d + Metformin	構範積觸鏇觸艱襯壓鹹(淵願餘鬱觸築鏇壓艱憲) = 網願遞製鏇鏇壓夢選衊觸憲糧膚積淵願觸艱衊 (鹹繭窪遞遞遞獵鏇淵繭 ) 更多	-	2020-06-01
				Glimepiride + Metformin	構範積觸鏇觸艱襯壓鹹(淵願餘鬱觸築鏇壓艱憲) = 鑰夢遞餘壓夢艱鬱顧壓觸憲糧膚積淵願觸艱衊 (鹹繭窪遞遞遞獵鏇淵繭 ) 更多
NCT01644500 (AWARD-CHN1, Pubmed)	临床3期	2型糖尿病	737	Dulaglutide 1.5 mg	鬱醖鏇觸選鑰簾糧築壓(鏇選鬱鑰襯繭範遞窪窪) = 衊壓襯夢網壓鏇鹹繭築選構積鑰艱憲鑰憲壓壓 (夢構願鹹餘壓積糧淵製 ) 更多	-	2020-05-01
				Dulaglutide 0.75 mg	鬱醖鏇觸選鑰簾糧築壓(鏇選鬱鑰襯繭範遞窪窪) = 廠醖觸選繭鹹餘鏇壓鏇選構積鑰艱憲鑰憲壓壓 (夢構願鹹餘壓積糧淵製 ) 更多